O-desmethylvenlafaxine Synthesis Using Weak Bases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for producing O-desmethylvenlafaxine involve hazardous chemicals, result in impure products with low yield, and require multiple costly purification steps, making them inefficient for large-scale production.
Innovation Solution
A process involving the reduction of 1-[cyano(p-substituted benzyloxyphenyl)methyl]cyclohexanol with sodium borohydride-iodine or sodium borohydride-trifluoroacetic acid, followed by alkylation and deprotection, using safer reagents and fewer purification steps to produce O-desmethylvenlafaxine with improved yield and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Temperature
If n-butyl lithium is used as a strong base for condensation reaction, then the reaction can proceed at lower temperature, but it causes fire hazard and forms more impurities
Solution Approach 1:
The patent changes the base parameter from strong base (n-butyl lithium) to weak base (pyridine or triethylamine), and changes the temperature parameter from low temperature (−80° to −50° C.) to ambient or elevated temperature (0° to 100° C.), thereby eliminating fire hazard and impurity formation while maintaining reaction effectiveness
Solution Approach 2:
The patent replaces hazardous n-butyl lithium with safer, more stable weak bases like pyridine or triethylamine that are easier to handle and eliminate the need for specialized low-temperature equipment, making the process more suitable for large-scale production
2Manufacturing precision
If multiple crystallization steps are used for purification, then product purity can be improved, but production time and cost increase
Solution Approach 1:
The patent extracts and removes harmful impurities at the source by using weak bases that do not form difficult-to-remove salts, and employs selective extraction techniques to separate impurities from the product in fewer steps, thereby reducing purification time while maintaining high purity
Solution Approach 2:
The patent introduces weak bases as intermediary substances that facilitate the reaction and can be easily separated from the product mixture, acting as mediators that simplify the purification process and reduce the number of crystallization steps required
3Productivity
If hazardous chemicals are used in the process, then certain reactions can be achieved, but safety risks and production costs increase
Solution Approach 1:
The patent converts the previously harmful strong base condition into beneficial weak base conditions, where the mildness of pyridine or triethylamine actually benefits the reaction by avoiding unwanted side reactions and simplifying workup, while eliminating safety hazards and reducing operational complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves higher yield and purity of O-desmethylvenlafaxine with reduced impurities and eliminates the need for hazardous chemicals, making it more cost-effective and suitable for large-scale production.
Implementation Method 1
reducing 1-[cyano(p-substituted benzyloxyphenyl)methyl]cyclohexanol of formula (II) with a reducing agent sodiumborohydride-iodine or sodiumborohydride-trifluoroacetic acid in presence of a solvent to obtain 1-[2-amino-1-(substituted benzyloxyphenyl)ethyl]cyclohexanol of formula (III)
Data Source
AI summary
The present invention relates to an improved, process for large scale production of 1-[2-(dimethylamino)-1-(4-phenol)ethyl]cyclohexanol (O-desmethylvenlafaxine) or its pharmaceutically acceptable salts with increased yield and minimal impurities.